These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16417813)

  • 21. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
    Klawiter EC; Cross AH; Naismith RT
    Neurology; 2009 Sep; 73(12):984-90. PubMed ID: 19770475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon beta 1a.
    Pozzilli C; Koudriavtseva T
    Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
    Chofflon M
    BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab versus interferon beta-1a: implications for pathology and trial design.
    McFarland HF
    Lancet Neurol; 2009 Jan; 8(1):26-8. PubMed ID: 19081510
    [No Abstract]   [Full Text] [Related]  

  • 25. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 26. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 27. Introduction.
    Owens GM
    J Manag Care Pharm; 2013; 19(1 Suppl A):S3. PubMed ID: 23383727
    [No Abstract]   [Full Text] [Related]  

  • 28. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
    Bencsik K; Rajda C; Füvesi J; Járdánházy T; Török M; Vécsei L
    Swiss Med Wkly; 2002 May; 132(17-18):237. PubMed ID: 12087490
    [No Abstract]   [Full Text] [Related]  

  • 29. 10 years of interferon beta-1b (Beta feron therapy.
    Kappos L; Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
    [No Abstract]   [Full Text] [Related]  

  • 30. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 31. Disease modifying therapies in multiple sclerosis.
    Fox RJ; Fisher E; Rudick R
    Neurology; 2002 Aug; 59(3):471-2; author reply 472-3. PubMed ID: 12177396
    [No Abstract]   [Full Text] [Related]  

  • 32. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Betaferon and therapy of multiple sclerosis--present and future].
    Hohlfeld R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():1. PubMed ID: 11603109
    [No Abstract]   [Full Text] [Related]  

  • 34. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
    Barnes CJ; Caon C; Foley JF; Friedman M; Menzin J; Nair KV; Nichols C; Olvey EL; Owens GM; Pill MW; Skrepnek GH; White LA; Zerkowski K
    J Manag Care Pharm; 2013; 19(1 Suppl A):S1-53. PubMed ID: 23383730
    [No Abstract]   [Full Text] [Related]  

  • 35. [Interferon beta-1a].
    Taéron C
    Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
    [No Abstract]   [Full Text] [Related]  

  • 36. Patients' views of interferon therapy in MS.
    Burgess M
    Prof Nurse; 1998 Jun; 13(9):588-92. PubMed ID: 9782975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S; Manger B; Kern P; Kalden J
    Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
    Christopher V; Scolding N; Przemioslo RT
    J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.